Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Sol-Gel Technologies Ltd. (4SG.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
4.3400+0.0400 (+0.93%)
At close: 08:00AM CET
Advertisement

Sol-Gel Technologies Ltd.

7 Golda Meir Street
Weizmann Science Park
Ness Ziona 7403650
Israel
972 8 931 3433
https://www.sol-gel.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees53

Key Executives

NameTitlePayExercisedYear Born
Dr. Alon Seri-LevyCo-Founder, CEO & Director567kN/A1961
Mr. Gilad MamlokChief Financial Officer469kN/A1968
Mr. Moshe ArkinExec. ChairmanN/AN/A1953
Prof. David AvnirCo-FounderN/AN/AN/A
Dr. Itzik YosefChief Operating OfficerN/AN/A1976
Dr. Karine NeimannVP of Projects & Planning and Chief ChemistN/AN/A1971
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Corporate Governance

Sol-Gel Technologies Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement